Yogendra Singh

Yogendra Singh

Yogendra Singh is the founder and editor of Structural Signals, an independent publication covering long-term trends in technology, economics, energy, geopolitics and society.

The Fertility Gold Rush

IVF laboratory specialist working with a microscope in a fertility clinic

As fertility rates fall, private equity is turning fertility care into a fast growing healthcare roll up. Fertility rates are falling across much of the developed world. Yet one corner of reproductive healthcare is expanding rapidly. Private equity firms have…

The Buy Now, Pay Later Trap

Person shopping online with a credit card while browsing products on a laptop, illustrating Buy Now Pay Later and digital checkout financing.

How Splitting a Payment Became a Shadow Credit System An old idea, moving faster For most of modern retail history, the question that stood between a person and a purchase was simple: can I afford this? Now a second question…

The Pet Premium

Pet owner with a dog during a veterinary checkup, highlighting the growing cost of pet healthcare and permanent household spending.

Why Pets Have Become a Permanent Household Expense Household budgets have historically had a short list of fixed line items: rent or mortgage, utilities, groceries, transportation, and for those with kids, childcare. A new dependent has effectively joined that list…

The Compliance Trap

Modern corporate skyscrapers representing the growing compliance burden and competitive advantage of large companies in regulated industries.

Why More Rules Often Strengthen the Biggest Companies Every large company now runs two operations at once. One makes the product. The other exists to prove, in writing, that the product was made correctly. The second operation is expensive, and…

The Local Advantage

Large container port showing global shipping, logistics infrastructure, and international supply chains.

Why Geography Is Beating Globalization Again Geography was supposed to stop mattering. Container shipping, free trade agreements, and the internet promised a world where a company could build almost anywhere and sell everywhere. For a while, that promise held. Today…

The Antibiotic Paradox

Scientists conducting pharmaceutical research in a laboratory developing new medicines, illustrating the economic challenges of antibiotic innovation.

Why Nobody Can Justify Building the Medicine We’ll Need Most In April 2019, a small California biotech called Achaogen filed for bankruptcy. Ten months earlier, the company had done something genuinely rare: it won FDA approval for a new antibiotic,…